Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Pfizer Maternal Covid-19 Vaccine Trial has launched at Oxford University Hospitals NHS Foundation Trust for women between 27-34 weeks pregnant. The Nuffield Department of Women’s & Reproductive Health’s team of doctors, research midwives and nurses are delivering this critical trial to evaluate the safety, tolerability, and immunogenicity of the Pfizer vaccine in pregnant women.

Pregnant woman

For the first time in the UK, a Covid-19 vaccine study for pregnant women has launched. It seeks to learn about the safety and effectiveness of the Pfizer Maternal Covid-19 Vaccine for all expectant mothers and their babies.

A local Covid-19 research study will compare an investigational (study) vaccine against a placebo to see if the study vaccine can prevent Covid-19. 

This national study is led by the National Institute for Health Research. Managing the study for the John Radcliffe Hospital in Oxford, is the OSPREA Team of research midwives and nurses who are part of the Nuffield Department of Women's & Reproductive Health

Read more about the Pfizer Maternal Covid-19 Vaccine Trial